EXPLORING UNCERTAINTY IN ECONOMIC EVALUATION OF MEDICINES: A REVIEW OF THE FIRST MANUFACTURERS' SUBMISSIONS TO THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)

被引：4
|
作者：
Ghabri, S. [1 ]
Hamers, F. F. [1 ]
Josselin, J. M. [2 ]
Harousseau, J. L. [1 ]
机构：
[1] HAS, La Plaine St Denis, France
[2] Univ Rennes 1, Rennes, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1160
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP224
引用
收藏
页码：A441 / A442
页数：2
相关论文
共 50 条
  • [1] Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health
    Ghabri, Salah
    Hamers, Francoise F.
    Josselin, Jean Michel
    [J]. PHARMACOECONOMICS, 2016, 34 (06) : 617 - 624
  • [2] Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers’ Submissions to the French National Authority for Health
    Salah Ghabri
    Françoise F. Hamers
    Jean Michel Josselin
    [J]. PharmacoEconomics, 2016, 34 : 617 - 624
  • [3] INCLUSION OF ADVERSE EVENTS IN THE ECONOMIC EVALUATION OF HEALTH TECHNOLOGIES: A REVIEW OF THE MANUFACTURERS' SUBMISSIONS TO THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)
    Lam, L.
    Ghabri, S.
    [J]. VALUE IN HEALTH, 2019, 22 : S609 - S609
  • [4] Health-state utility estimates for health technology assessment: a review of the manufacturers' submissions to the French National Authority for Health
    Hamers, Francoise F.
    Ghabri, Salah
    Le Gales, Catherine
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (05) : 489 - 494
  • [5] THE PRINCIPLES OF THE ECONOMIC EVALUATION AND PUBLIC HEALTH COMMITTEE (CEESP) DOCTRINE AT THE FRENCH NATIONAL AUTHORITY FOR HEALTH (HAS)
    Fahfouhi, Y.
    Sion, M.
    Ghabri, S.
    Paris, V
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S170 - S170
  • [6] Involving patients in the evaluation of health technologies at the French National Authority for Health (HAS)
    Nabarette, Herve
    [J]. SANTE PUBLIQUE, 2018, 30 (06): : 767 - 775
  • [7] IS THERE A THRESHOLD IN FRANCE?: FIRST EXHAUSTIVE REVIEW OF PUBLISHED HEALTH-ECONOMIC APPRAISALS BY THE HAUTE AUTORITE DE SANTE (HAS), (FRENCH NATIONAL AUTHORITY FOR HEALTH)
    Cartier-Bechu, C.
    Gherardi, A.
    Sivignon, M.
    Pignata, M.
    Petitjean, A.
    Monnier, R.
    Roze, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A490 - A490
  • [8] How the French national authority for health assesses medicines for use in pediatrics
    Rebstock, Chole
    Mussetta, Bertrand
    Martinez, Sandrine
    Diatta, Thierno
    Desbiolles, Alice
    Alberti, Corinne
    Niaudet, Patrick
    Viaux-Savelon, Sylvie
    Cochat, Pierre
    Mercier, Jean-Christophe
    [J]. ARCHIVES DE PEDIATRIE, 2024, 31 (05): : 285 - 292
  • [9] Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies
    Xoxi, Entela
    Di Bidino, Rossella
    Leone, Serena
    Aiello, Andrea
    Prada, Mariangela
    [J]. FRONTIERS IN MEDICAL TECHNOLOGY, 2022, 4
  • [10] Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health
    Raimond, Veronique
    Kaltenbach, Emmanuelle
    Adam, Christophe
    Lazzarotto, Sebastien
    Le Gales, Catherine
    Perrier, Lionel
    Wittwer, Jerome
    [J]. BULLETIN DU CANCER, 2021, 108 (12) : 1162 - 1169
12345